Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements relating to Immunic AG, including statements about our pending transaction with
Vital Therapies. Risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: the risk that the stockholders of Vital Therapies do not
approve the proposed transaction with Immunic, the ability of the parties to close the proposed transaction, and Immunic’s expected listing of Immunic, Inc. on NASDAQ. Forward-looking statements are identified by the use of forward-looking
terminology including “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “plans,” “pro forma,” “estimates,” or
“anticipates” or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. All statements other than statements of historical fact are statements that could be deemed forward-looking
statements. These forward-looking statements should not be relied upon as predictions of future events as Immunic cannot assure investors that the events or circumstances reflected in these statements will be achieved or will occur. The
forward-looking statements in this press release represent Immunic’s views as of the date of this press release. Immunic anticipates that subsequent events and developments will cause its views to change. Immunic may elect to update these
forward-looking statements at some point in the future, however, it has no current intention of doing so except to the extent required by applicable law. Investors should, therefore, not rely on these forward-looking statements as representing
Immunic’s views as of any date subsequent to the date of this press release.
Additional Information about the Proposed Transaction between
Vital Therapies, Inc. and Immunic AG and Where to Find It
In connection with the proposed transaction, Vital Therapies and Immunic intend to file
relevant materials with the Securities and Exchange Commission, or the SEC, and Vital Therapies has filed a registration statement on Form
S-4
and a final proxy statement/prospectus. The registration statement
was declared effective by the SEC on February 14, 2019, and the definitive proxy statement was first mailed or otherwise made available to Vital Therapies stockholders on February 19, 2019. Investors and security holders of Vital Therapies
and Immunic are urged to read the final proxy statement/prospectus (including any amendments or supplements thereto) and other documents filed with the SEC when they become available because they contain important information about Vital Therapies,
Immunic and the proposed transaction. In addition to receiving the final proxy statement/prospectus and proxy card by mail, Vital Therapies stockholders can also obtain the final proxy statement/prospectus, as well as other filings containing
information about Vital Therapies, without charge, from the SEC’s website (http://www.sec.gov) or, without charge, by directing a written request to: Vital Therapies, Inc.,
15222-B
Avenue of Science, San
Diego, CA, 92128, Attention: Investor Relations.
This communication does not constitute a solicitation of proxy, an offer to purchase or a solicitation
of an offer to sell any securities.
Vital Therapies and its executive officers and directors may be deemed to be participants in the solicitation of
proxies from Vital Therapies’ stockholders with respect to the matters relating to the proposed transaction. Immunic may also be deemed a participant in such solicitation. Information regarding Vital Therapies’ executive officers and
directors is available in Vital Therapies’ proxy statement on Schedule 14A for its 2018 annual meeting of stockholders, filed with the SEC on April 12, 2018. Information regarding any interest that Vital Therapies, Immunic or any of the
executive officers or directors of Vital Therapies or Immunic may have in the transaction with Immunic is set forth in the
